Department of Cardiology, University of Groningen, Groningen, The Netherlands.
National Heart Centre Singapore, Singapore.
Eur J Heart Fail. 2020 Nov;22(11):2102-2111. doi: 10.1002/ejhf.1674. Epub 2019 Dec 3.
Cathepsin D is a ubiquitous lysosomal protease that is primarily secreted due to oxidative stress. The role of circulating cathepsin D in heart failure (HF) is unknown. The aim of this study is to determine the association between circulating cathepsin D levels and clinical outcomes in patients with HF and to investigate the biological settings that induce the release of cathepsin D in HF.
Cathepsin D levels were studied in 2174 patients with HF from the BIOSTAT-CHF index study. Results were validated in 1700 HF patients from the BIOSTAT-CHF validation cohort. The primary combined outcome was all-cause mortality and/or HF hospitalizations. Human pluripotent stem cell-derived cardiomyocytes were subjected to hypoxic, pro-inflammatory signalling and stretch conditions. Additionally, cathepsin D expression was inhibited by targeted short hairpin RNAs (shRNA). Higher levels of cathepsin D were independently associated with diabetes mellitus, renal failure and higher levels of interleukin-6 and N-terminal pro-B-type natriuretic peptide (P < 0.001 for all). Cathepsin D levels were independently associated with the primary combined outcome [hazard ratio (HR) per standard deviation (SD): 1.12; 95% confidence interval (CI) 1.02-1.23], which was validated in an independent cohort (HR per SD: 1.23, 95% CI 1.09-1.40). In vitro experiments demonstrated that human stem cell-derived cardiomyocytes released cathepsin D and troponin T in response to mechanical stretch. ShRNA-mediated silencing of cathepsin D resulted in increased necrosis, abrogated autophagy, increased stress-induced metabolism, and increased release of troponin T from human stem cell-derived cardiomyocytes under stress.
Circulating cathepsin D levels are associated with HF severity and poorer outcome, and reduced levels of cathepsin D may have detrimental effects with therapeutic potential in HF.
组织蛋白酶 D 是一种普遍存在的溶酶体蛋白酶,主要因氧化应激而分泌。循环组织蛋白酶 D 在心力衰竭(HF)中的作用尚不清楚。本研究旨在确定循环组织蛋白酶 D 水平与 HF 患者临床结局的相关性,并探讨诱导 HF 中组织蛋白酶 D 释放的生物学机制。
在 BIOSTAT-CHF 指数研究中对 2174 例 HF 患者进行了组织蛋白酶 D 水平研究。结果在 BIOSTAT-CHF 验证队列的 1700 例 HF 患者中得到验证。主要联合结局为全因死亡率和/或 HF 住院。将人多能干细胞衍生的心肌细胞置于缺氧、促炎信号和拉伸条件下。此外,通过靶向短发夹 RNA(shRNA)抑制组织蛋白酶 D 的表达。较高的组织蛋白酶 D 水平与糖尿病、肾功能衰竭以及白细胞介素-6 和 N 末端 pro-B 型利钠肽(P < 0.001)水平升高独立相关。组织蛋白酶 D 水平与主要联合结局独立相关[每标准差(SD)的危险比(HR):1.12;95%置信区间(CI)1.02-1.23],在独立队列中得到验证(每 SD 的 HR:1.23,95%CI 1.09-1.40)。体外实验表明,人类干细胞衍生的心肌细胞在机械拉伸下释放组织蛋白酶 D 和肌钙蛋白 T。shRNA 介导的组织蛋白酶 D 沉默导致坏死增加、自噬减少、应激诱导的代谢增加以及应激下人干细胞衍生的心肌细胞中肌钙蛋白 T 的释放增加。
循环组织蛋白酶 D 水平与 HF 严重程度和预后不良相关,降低组织蛋白酶 D 水平可能对 HF 具有潜在的不利影响并具有治疗潜力。